MAPT and Alzheimer disease: We suggest that p-tau may target a pathway(s) that is shared by many different cell types, and that pharmacological control of this pathway(s) may lead to the discovery of novel, efficacious AD drugs targeting the pathogenicity of abnormally phosphorylated tau.